Liquid chromatography tandem mass spectrometry method for the quantification of amisulpride with LLOQ of 100 pg/mL using 100 μL of plasma

Biomedical Chromatography

Volumn 22, Issue 12, 2008, Pages 1424-1433

  Nirogi, Ramakrishna ^a   Bhyrapuneni, Gopinadh ^a,b   Kandikere, Vishwottam ^a   Mudigonda, Koteshwara ^a   Ajjala, Devender ^a   Suraneni, Ramakrishna ^a   Mukkanti, K ^b  

^a SUVEN LIFE SCIENCES LTD   (India)

^b JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

Author keywords

Amisulpride; Liquid chromatography tandem mass spectrometry; Plasma

Indexed keywords

HIGH PRESSURE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PLASMA (HUMAN); POSITIVE IONS;

AMISULPRIDE; ANALYTES; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN PLASMAS; ISOCRATIC MOBILE PHASE; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY; LIQUID-LIQUID EXTRACTION; POSITIVE ION ELECTROSPRAY TANDEM MASS SPECTROMETRIES; REVERSE-PHASE COLUMN;

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

AMISULPRIDE; ETICLOPRIDE; DOPAMINE RECEPTOR BLOCKING AGENT; DRUG DERIVATIVE; SULPIRIDE; SULTOPRIDE;

ACCURACY; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG STABILITY; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; FREEZING; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; NORMAL HUMAN; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; THAWING; VOLUNTEER; BLOOD; CHEMICAL STRUCTURE; CHEMISTRY; METHODOLOGY; REPRODUCIBILITY;

CHROMATOGRAPHY, LIQUID; DOPAMINE ANTAGONISTS; HUMANS; MOLECULAR STRUCTURE; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SULPIRIDE; TANDEM MASS SPECTROMETRY;

EID: 59649126067     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1076     Document Type: Article

References (28)

1. Bergemann N, Kopitz J, Kress KR and Frick A. Plasma amisulpride levels in schizophrenia or schizoaffective disorder. European Neuropsychopharmacology 2004; 14: 245.
2. Bohbot M, Doare L and Diquet B. Determination of a new benzamie, amisulpride, in human plasma by reversed-phase ion-pair high-performance liquid chromatography. Journal of Chromatography 1987; 416: 414.
3. Castelli MP, Mocci I, Sanna AM, Gessa GL and Pani L. (-)S amisulpride binds with high affinity to cloned dopamine D(3) and D(2) receptors. European Journal of Pharmacology 2001; 432: 143.
4. Colonna L, Saleem P, Dondey-Nouvel L, Rein W and The Amisulpride Study Group. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. International Clinical Psychopharmacology 2000; 15: 13.
5. Curran MP and Perry CM. Amisulpride. A review of its use in the management of schizophrenia. Drugs 2001; 61: 2123.
6. Danion J, Rein W, Fleurot O and The Amisulpride Study Group. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. American Journal of Psychiatry 1999; 156: 610.
7. Davis JM, Chen N and Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Archives in General Psychiatry 2003; 60: 553.
8. Frahnert C, Rao ML and Grasmader K. Analysis of eighteen antidepressants, four atypical antipsychotics and active metabolites in serum by liquid chromatography: a simple tool for therapeutic drug monitoring. Journal of Chromatography B 2003; 794: 35.
9. Gschwend MH, Arnod P, Ring J and Martin W. Selective and sensitive determination of amisulpride in human plasma by liquid chromatography-tandem mass spectrometry with positive electrospray onization and multiple reaction monitoring. Journal of Chromatography B 2006; 831: 132.
10. Hsieh Y and Korfmacher WA. Increasing speed and throughput when using HPLC-MS/MS systems for drug metabolism and pharmacokinetic screening. Current Drug Metabolism 2006; 7: 479.
11. Kirchherr H and Kuhn-Velten WN. Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach. Journal of Chromatography B 2006; 843: 100.
12. Kratzsch C, Peters FT, Kraemer T, Weber AA and Maurer HH. Screening, library-assisted identification and validated quantification of fifteen neuroleptics and three of their metabolites in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization. Journal of Mass Spectrometry 2003; 38: 283.
13. Lambert M and Naber D. Amisulpride in atypisches Antipsychotikum in der Behandlung schizophrener Erkrankungen. Fundamental Psychiatry 1999; 13: 43.
14. Lecrubier Y, Azorin M, Bottai T, Dalery J, Garreau G, Lemperiere T, Lisoprawski A, Petitjean F and Vanelle JM. Consensus on the practical use of amisulpride, an atypical antipsychotic, in the treatment of schizophrenia. Neuropsychobiology 2000; 44: 41.
15. Leucht S, Pitschel-Walz G, Engel RR and Kissling W. Amisulpride, an unusual 'atypical' antipsychotic: a meta-analysis of randomized controlled trials. American Journal of Psychiatry 2002; 159: 180.
16. Malavasi B, Locatelli M, Ripamonti M and Ascalone V. Determination of amisulpride, a new benzamide derivative, in human plasma and urine by liquid-liquid extraction or solid-phase extraction in combination with high-performance liquid chromatography and fluorescence detection-application to pharmacokinetics. Journal of Chromatography B 1996; 676: 107.
17. McKeage K and Plosker GL. Amisulpride: a review of its use in the management of schizophrenia. CNS Drugs 2004; 18: 933.
18. Mortiner AM. How do we choose between atypical antipsychotics? The advantages of amisulpride. International Journal of Neuropsychopharmacology 2004; 7(suppl 1): 21.
19. Moulin A, Truffer D, Rauch-Desanti C, Istin M, Grognet JM and Dufour A. Comparison of HPLC and RIA methods applied to the quantification of amisulpride in human plasma. European Journal of Drug Metabolism and Pharmacokinetics 1991(Special issue no. 3); 507.
20. Muller N, Riedel M and Moller HJ. Amisulprid in der Therapie schizophrener Negativsymptomatik. Psychopharmakotherapie 2000; 7: 111.
21. Noble S and Benfield P. Amisulpride: a review of its clinical potential in dysthymia. CNS Drugs 1999; 12: 471.
22. Pehourcq F, Ouariki S and Begaud B. Rapid high-performance liquid chromatographic measurement of amisulpride in human plasma: application to manage acute intoxication. Journal of Chromatography B 2003; 789: 101.
23. Peuskens J, Bech P, Moller HJ, Bale R, Fleurot O, Reim W and The Amisulpride Study Group. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Research 1999; 88: 107.
24. Peuskens J, Moller HJ and Puech A. Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. European Neuropsychopharmacology 2002; 12: 305.
25. Racagni G, Canonico PL, Ravizza L, Pani L and Amore M. Consensus on the use of substituted benzamides in psychiatric patients. Neuropsychobiology 2004; 50: 134.
26. Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I and Bianchetti G. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Human Psychopharmacology 2002; 17: 1.
27. Sachse J, Hartter S, Weigmann H and Hiemke C. Automated determination of amisulpride by liquid chromatography with column switching and spectrophotometric detection. Journal of Chromatography B 2003; 784: 405.
28. Xiberas X, Martinot JL, Mallet L, Artiges E, Canal M, Loc'h C, Maziere B and Paillere-Martinot ML. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. Journal of Clinical Psychopharmacology 2001; 21: 207.